, Tracking Stock Market Picks
Enter Symbol:
Accelrys, Inc. (ACCL) [hlAlert]

up 55.01 %

Accelrys, Inc. (ACCL) rated Buy with price target $10 by Cantor Fitzgerald

Posted on: Wednesday,  Jun 27, 2012  8:25 AM ET by Cantor Fitzgerald

Cantor Fitzgerald rated Buy Accelrys, Inc. (NASDAQ: ACCL) on 06/27/2012, when the stock price was $8.07. Since
then, Accelrys, Inc. has gained 55.02% as of 04/29/2014's recent price of $12.51.
If you would have followed this Cantor Fitzgerald's recommendation on ACCL, you would have gained 55.01% of your investment in 671 days.

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease and four partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, metabolic and inflammatory diseases. Four additional partnered compounds are in preclinical development.

Cantor U.S. Equity Research provides timely and insightful opinions on select stocks. We look at key drivers of the stock price, including company and industry fundamentals, capital markets influences and overall economic trends to provide critical and in-depth analysis. Our focus is on small and mid-cap companies in the following sectors: * Marine Transportation * Life Sciences * Clean Technology & Energy Efficiency * Real Estate * Communications Technology * Internet * Enterprise Software
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/27/2012 8:25 AM Buy
8.07 10.00
as of 12/31/2012
1 Week down  -4.13 %
1 Month up  2.72 %
3 Months up  4.50 %
1 YTD up  12.14 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy